Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience

被引:18
作者
Bompart, Francois [1 ]
Kiechel, Jean-Rene [2 ]
Sebbag, Robert [1 ]
Pecoul, Bernard [2 ]
机构
[1] Sanofi Aventis, Access Med Dept, F-94255 Gentilly, France
[2] Drugs Neglected Dis Initiat, CH-1202 Geneva, Switzerland
关键词
ARTESUNATE-AMODIAQUINE COMBINATION; EFFICACY; SAFETY;
D O I
10.1186/1475-2875-10-143
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: This case study describes how a public-private partnership initiated to develop a new anti-malarial combination, ASAQ Winthrop, has evolved over time to address issues posed by its effective deployment in the field. Case description: In 2002, DNDi created the FACT project to develop two fixed-dose combinations, artesunate-amodiaquine and artesunate-mefloquine, to meet the WHO anti-malarial treatment recommendations and international regulatory agencies approval standards. In 2002, Sanofi-aventis had started a development programme for a fixed-dose combination of artesunate and amodiaquine, to replace its co-blister combination. DNDi and sanofi-aventis joined forces in 2004, with the objective of developing within the shortest possible time frame a non-patented, affordable and easy to use fixed-dose combination of artesunate and amodiaquine adapted to the needs of patients, in particular, those of children. The partners developed Coarsucam (R)/Artesunate Amodiaquine Winthrop (R) ("ASAQ Winthrop") which was prequalified by the WHO in 2008. Additional partnerships have since been established by DNDi and sanofi-aventis to ensure: 1) the adoption of this new medicine by malaria-endemic countries, 2) its appropriate usage through a broad range of information tools, and 3) the monitoring of its safety and efficacy in the field through an innovative Risk Management Plan. Discussion and evaluation: The partnership between DNDi and sanofi-aventis has enabled the development and pre-qualification of ASAQ Winthrop in a short timeframe. As a result of the multiple collaborations established by the two partners, as of late 2010, ASAQ Winthrop was registered in 30 sub-Saharan African countries and in India, with over 80 million treatments distributed in 21 countries. To date, 10 clinical studies, involving 3432 patients with ASAQ Winthrop were completed to document efficacy and safety issues identified in the Risk Management Plan. Conclusions: The speed at which ASAQ Winthrop was adopted in the field shows that this drug fits the needs of patients and health authorities. It also demonstrates the power of partnerships that combine different sets of strengths and skills, and that evolve to include additional actors to meet new global health challenges for poverty-related diseases.
引用
收藏
页数:9
相关论文
共 16 条
[1]  
Affordable medicines facility-malaria (AMFm), AFFORDABLE MED FACIL
[2]  
[Anonymous], 2009, WORLD MAL REP 2009
[3]  
[Anonymous], 2010, Guidelines for the treatment of Malaria, DOI DOI 10.1080/03630269.2023.2168201
[4]  
DALESSANDRO U, 2010, P AM SOC TROP MED HY
[5]   Comparison of Sulfadoxine-Pyrimethamine, Unsupervised Artemether-Lumefantrine, and Unsupervised Artesunate-Amodiaquine Fixed-Dose Formulation for Uncomplicated Plasmodium falciparum Malaria in Benin: A Randomized Effectiveness Noninferiority Trial [J].
Faucher, Jean-Francois ;
Aubouy, Agnes ;
Adeothy, Adicat ;
Cottrell, Gilles ;
Doritchamou, Justin ;
Gourmel, Bernard ;
Houze, Pascal ;
Kossou, Hortense ;
Amedome, Hyacinthe ;
Massougbodji, Achille ;
Cot, Michel ;
Deloron, Philippe .
JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (01) :57-65
[6]   Fixed artesunate-amodiaquine combined pre-formulation study for the treatment of malaria [J].
Kauss, Tina ;
Fawaz, Fawaz ;
Guyot, Michel ;
Lagueny, Anne-Marie ;
Dos Santos, Isabelle ;
Bonini, Francois ;
Olliaro, Piero ;
Caminiti, Antonella ;
Millet, Pascal .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 395 (1-2) :198-204
[7]  
LACAZE C, 2011, MALAR J
[8]   Randomized, multicentre assessment of the efficacy and safety of ASAQ - a fixed-dose artesunate-amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria [J].
Ndiaye, Jean Louis ;
Randrianarivelojosia, Milijaona ;
Sagara, Issaka ;
Brasseur, Philippe ;
Ndiaye, Ibrahima ;
Faye, Babacar ;
Randrianasolo, Laurence ;
Ratsimbasoa, Arsene ;
Forlemu, Doris ;
Moor, Vicky Ama ;
Traore, Aminata ;
Dicko, Yahia ;
Dara, Niawanlou ;
Lameyre, Valerie ;
Diallo, Mouctar ;
Djimde, Abdoulaye ;
Same-Ekobo, Albert ;
Gaye, Oumar .
MALARIA JOURNAL, 2009, 8
[9]  
NDIAYE JLA, 2010, P AM SOC TROP MED HY
[10]  
PECOUL B, 2008, HLTH PARTNERSHIPS RE